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 INTRODUCTION
 Ulcerative colitis (UC) is a chronic, progressive infl ammatory 
bowel disease characterized by mucosal infl ammation of the colon. 
Th e clinical features include bloody diarrhea, abdominal pain, fecal 
incontinence, urgency, and tenesmus  ( 1,2 ) . Although the cause of 
UC remains unknown, the important role of tumor necrosis fac-
tor (TNF) in the pathogenesis has become accepted on the basis 
of empiric data  ( 3 ). Current treatment goals for patients with UC 
include induction of remission and mucosal healing, avoidance of 
hospitalization and colectomy, and improving quality of life.
 Adalimumab, a fully human monoclonal antibody specifi c for 
human TNF, is approved worldwide for multiple indications, 
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including UC  ( 4,5 ). Th e effi  cacy of adalimumab in inducing and 
maintaining remission, up to 52 weeks, in patients with mod-
erately to severely active UC was demonstrated in the pivotal 
ULTRA ( U lcerative Colitis  L ong- T erm  R emission and Main-
tenance with  A dalimumab) 1 and 2 clinical trials that evaluated 
patients whose disease was active despite treatment with conven-
tional therapies  ( 6–9 ) . Adalimumab was also shown to reduce the 
number of all-cause and UC-related hospitalizations compared 
with placebo treatment. Colectomy rates were low in the ULTRA 1 
and 2 studies and did not diff er signifi cantly between adalimumab- 
and placebo-treated patients  ( 10 ) . Th e safety of adalimumab has 
been extensively studied in patients with rheumatoid arthritis, 
Crohn’s disease, and other infl ammatory disorders  ( 11 ) ; yet, long-
term data from patients with UC are lacking. Th e ongoing, open-
label extension study, ULTRA 3, is evaluating the long-term safety 
and effi  cacy of adalimumab in patients with UC. In this report 
we present remission and mucosal healing rates, improvement in 
health-related quality of life and work productivity, and reduction 
of hospitalization rates with prolonged adalimumab maintenance 
treatment, up to 4 years, using data from patients who received 
adalimumab during ULTRA 1, ULTRA 2, or ULTRA 3. Th e safety 
profi le of long-term adalimumab therapy is also reported.
 METHODS
 ULTRA 1 and ULTRA 2 trial designs
 Detailed information regarding the designs and patient disposi-
tions of ULTRA 1 and ULTRA 2 has been published previously. 
 ( 6,7 ) Briefl y, these were phase 3, double-blind, placebo-controlled 
clinical trials that assessed the effi  cacy and safety of adalimumab 
for the treatment of moderately to severely active UC in adult 
patients with a diagnosis of UC for at least 90 days, Mayo score of 
6–12, and endoscopy subscore ≥2, despite concurrent or previous 
treatment with oral corticosteroids and/or immunosuppressants. 
Patients who had previously been exposed to anti-TNF therapy 
were eligible for ULTRA 2. In both studies, corticosteroid tapering 
was allowed at or aft er week 8, at the discretion of the investiga-
tor, for patients who demonstrated a satisfactory clinical response.
 Th e original protocol for ULTRA 1 had a 12-week double-
blind phase in which anti-TNF-naive patients were randomized 
to receive placebo for 8 weeks or adalimumab 160/80 mg at weeks 
0/2, followed by 40 mg at weeks 4/6. At weeks 8/10, patients rand-
omized to placebo received adalimumab 160/80 mg, and patients 
randomized to adalimumab continued to receive adalimumab 
40 mg every other week. Aft er the study began, at the request of the 
European regulatory authorities, the protocol was amended to add 
a second adalimumab induction group of 80/40 mg at weeks 0/2, 
followed by 40 mg at weeks 4/6. Under the amended protocol, the 
double-blind period was reduced to 8 weeks. ULTRA 1 included 
a subset of patients who were enrolled under both the original 
protocol and the amended protocol. Patients who completed the 
double-blind phase of the trial (8 or 12 weeks) could enter an 
open-label phase during which all patients received adalimumab 
40 mg every other week. ULTRA 1 concluded at week 52. Dur-
ing the open-label phase, patients who experienced an inadequate 
response could escalate to 40 mg weekly. Inadequate response was 
defi ned as partial Mayo score (PMS, Mayo score without endos-
copy subscore) ≥baseline score on two consecutive visits at least 14 
days apart, for patients with baseline PMS 4–7. For patients with a 
baseline PMS 8–9, inadequate response was defi ned as PMS ≥7 on 
two consecutive visits at least 14 days apart.
 In ULTRA 2, patients were randomized to receive placebo or 
adalimumab (160/80 mg at weeks 0/2, followed by 40 mg every 
other week). Th e last study visit occurred at week 52. Patients 
with an inadequate response (same defi nition as above) could 
move to open-label adalimumab 40 mg every other week begin-
ning at week 12 and subsequently to 40 mg weekly for continued 
inadequate response.
 ULTRA 3
 All patients who completed ULTRA 1 or ULTRA 2 could enter the 
open-label extension, ULTRA 3. Patients who completed ULTRA 
2 on blinded therapy (either adalimumab or placebo) received 
open-label adalimumab 40 mg every other week in ULTRA 3. 
Patients who completed the lead-in study (ULTRA 1 or ULTRA 
2) on open-label adalimumab 40 mg every other week or weekly 
continued their same dosing regimens in ULTRA 3. For patients 
who entered ULTRA 3 from a blinded cohort or on open-label 
every other week dosing, escalation to 40 mg weekly dosing was 
allowed aft er week 12 of ULTRA 3 for inadequate response (same 
defi nition as in ULTRA 1 and 2) or disease fl are (defi ned as a 
PMS diff erence ≥3 compared with the baseline PMS of ULTRA 
3 on two consecutive visits at least 14 days apart). Increase to 
40 mg weekly was allowed at week 2 of ULTRA 3 or thereaft er 
for patients who entered ULTRA 3 with an inadequate response 
on open-label every other week dosing. Corticosteroid tapering 
was allowed aft er week 12 of ULTRA 3 for patients with a clinical 
response, but if corticosteroid tapering was begun in the lead-in 
study (ULTRA 1 or ULTRA 2), patients could continue their cor-
ticosteroid taper upon entry into ULTRA 3.
 Data analysis
 Th e long-term effi  cacy of adalimumab up to 4 years of treat-
ment was assessed in all patients randomized to adalimumab in 
ULTRA 1 and ULTRA 2 who received at least one dose of adali-
mumab (ADA), excluding 10 patients from GCP (Good Clinical 
Practice)-noncompliant sites (ADA Randomized Set,  N =600). 
Effi  cacy in the ADA Randomized Set was assessed through week 
208. Some of the patients in this analysis set (i.e., patients who dis-
continued prematurely from ULTRA 1, 2, or 3 and patients who 
did not enroll into ULTRA 3) did not have 208 weeks of adali-
mumab exposure. Of the 600 patients in the ADA Randomized 
Set, 199 remained on adalimumab at week 208. Patients who 
entered ULTRA 3 from either ULTRA 1 or ULTRA 2 (including 
patients who were randomized to placebo at lead-in study base-
line), with the exception of four patients from GCP-noncompliant 
sites (ADA Extension Set,  N =588), were analyzed to evaluate the 
maintenance effi  cacy of adalimumab from week 0 to week 156 
of ULTRA 3, which corresponds to week 208 from lead-in study 
baseline. Of the 588 patients enrolled in ULTRA 3, a total of 360 
© 2014 by the American College of Gastroenterology The American Journal of GASTROENTEROLOGY
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remained on adalimumab at the ULTRA 3 week 156 study visit. 
Subgroup analyses by previous anti-TNF use were also performed.
 Effi  cacy end points assessed in the ADA Randomized Set were 
remission per PMS (PMS ≤2 with no subscore >1), remission per 
Infl ammatory Bowel Disease Questionnaire (IBDQ) score (IBDQ 
score ≥170),  ( 12 ) and mucosal healing (endoscopy subscore ≤1). 
Discontinuation of corticosteroids and corticosteroid-free remis-
sion (full Mayo score ≤2 with no individual subscore >1 and dis-
continued corticosteroid use) were assessed in patients from the 
ADA Randomized Set who received corticosteroids at lead-in 
study baseline ( N =356). Maintenance of remission (per PMS) and 
maintenance of mucosal healing through year 3 of ULTRA 3 was 
assessed in patients from the ADA Extension Set who entered 
ULTRA 3 in remission per full Mayo score ( N =242) or with mucosal 
healing ( N =409), respectively. Because of the timing of endosco-
pies in ULTRA 3, rates of mucosal healing and remission per full 
Mayo score (reported as part of corticosteroid-free remission) are 
reported up to week 196 from lead-in study baseline. Maintenance 
of mucosal healing is reported up to week 144 of ULTRA 3, which 
corresponds to week 196 from lead-in study baseline.
 Work Productivity and Activity Impairment (WPAI) was 
assessed using the WPAI questionnaire  ( 13 ) in patients rand-
omized to adalimumab from ULTRA 2 ( N =248). WPAI question-
naires were not completed in ULTRA 1. Th e WPAI score consists 
of four components: an assessment of activity impairment in all 
patients and assessments of work time missed, impairment while 
working, and overall work impairment in employed individuals. 
Each score ranges from 0% (no impairment) to 100% (total loss 
of work productivity or activity). A decrease in scores indicates 
improvement, and lower scores signify little impact of disease on 
work and activity.
 Exposure-adjusted incidence rates of all-cause hospitalization 
(hospitalization for any reason), UC-related hospitalization (hos-
pitalization due to adverse events or complications related to UC, 
including those occurring because of UC-related surgery, UC-
related fl ares, and extraintestinal manifestations of UC), and colec-
tomy were assessed during ULTRA 3 in the ADA Extension Set, 
including four patients from GCP-noncompliant sites ( N =592). 
Patient-based incidence rates (number of patients with hospitali-
zations or colectomy per patient-years at risk) and event-based 
incidence rates (number of hospitalizations per total patient-years 
of follow-up time), given that patients could be hospitalized more 
than once, were calculated from the fi rst dose in ULTRA 3 until 15 
April 2013 or until 70 days aft er the last dose, whichever came fi rst.
 Clinical assessment
 PMS and WPAI questionnaires (ULTRA 2 only) were assessed at 
every study visit. PMS was determined using the worst patient-
reported stool frequency and rectal bleeding subscores from 3 
days before the study visit. Endoscopies were performed at base-
line and at weeks 8, 32 (in ULTRA 2 only), and 52 in ULTRA 
1 and 2, and every 48 weeks in ULTRA 3. Th e IBDQ question-
naire was completed at baseline, at weeks 4, 8 (20, 32 in ULTRA 
2 only), and 52 in ULTRA 1 and 2, and at every study visit during 
ULTRA 3. Adverse events were analyzed through 70 days aft er 
the last adalimumab dose for any patient who received at least 
one dose of adalimumab in ULTRA 1, 2, or 3 ( N =1,010), includ-
ing patients from GCP-noncompliant sites. In this analysis, the 
data cutoff  date for effi  cacy end points and safety is 15 April 2013. 
Adverse events were coded using Medical Dictionary for Regula-
tory Activities ( MedDRA) version 16.0.
 Statistical methods
 Mean WPAI scores, corticosteroid-free remission, and com-
plete discontinuation of corticosteroids were reported over time 
as observed values. Long-term remission rates over time (per 
PMS and per IBDQ score) and mucosal healing rates over time 
were analyzed using nonresponder imputation (NRI), whereby 
patients with missing data were assumed not to have achieved 
the end point. A modifi ed NRI was used to analyze remission 
per PMS in patients who remained on every other week dosing, 
whereby NRI was used for patients with missing data and at the 
point of moving to weekly dosing. Maintenance of remission per 
PMS and mucosal healing (for patients in the ADA Extension Set 
who entered ULTRA 3 in remission per full Mayo score or with 
mucosal healing, respectively) were analyzed using NRI and last 
observation carried forward (LOCF). For LOCF, the last nonmiss-
ing value was carried forward.
 Cox proportional hazards regression analysis was used to iden-
tify predictors of loss of remission in patients from the ADA 
Extension Set by fi tting one model per potential prognostic factor. 
Crude hazard ratios with 95% confi dence intervals and  P -values 
were calculated. Baseline variables of lead-in study (ULTRA 1 or 2) 
assessed were age, sex, weight, disease duration, site of UC, Mayo 
score, C-reactive protein (CRP), immunomodulator (IMM) use, 
corticosteroid use, aminosalicylate use, tobacco use, albumin con-
centration, and previous anti-TNF use. Variables assessed at the 
time of enrollment into ULTRA 3 were IMM use, corticosteroid 
use, CRP, and albumin concentration. Time-dependent variables 
(from time of enrollment into ULTRA 3 until loss of remission or 
last observation in ULTRA 3) assessed during ULTRA 3 were CRP 
levels and albumin concentration, and change in CRP and albumin 
concentration over time. Th e time to loss of remission (defi ned 
as PMS >2 for at least two consecutive visits) was measured for 
patients in the ADA Extension Set who were in remission per PMS 
at the time of enrollment into ULTRA 3 ( N =307).
 RESULTS
 Patient disposition and baseline characteristics
 Detailed patient demographics from ULTRA 1 and ULTRA 2 were 
reported previously  ( 6,7 ). Th e disposition of patients in ULTRA 3 
is shown in  Figure 1a . More than half of the patients who enrolled 
in the lead-in studies enrolled in ULTRA 3 (588/1,094, 53.7%). 
Fift y-four patients did not receive any adalimumab before enroll-
ing in ULTRA 3. Of the 588 patients analyzed in the ADA Exten-
sion Set, 56.8% (334/588) enrolled from ULTRA 1 and 43.2% 
(254/588) enrolled from ULTRA 2 ( Figure 1a ). Th e number of 
patients at each study visit in the ADA Randomized Set and ADA 
Extension Set is shown in  Figure 1b .
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 Baseline characteristics (from lead-in study) for the ADA Ran-
domized and ADA Extension Sets are shown in  Supplementary 
Table S1 online. A majority of patients were white males, and 
median disease duration was ∼ 6 years. Th e mean Mayo score was 
∼ 9, about half of the patients had pancolitis, and over half of the 
patients were using oral corticosteroids at lead-in study baseline. 
Th e rate of previous anti-TNF use was 16.2% in the ADA Rand-
omized Set and 13.9% in the ADA Extension Set. Baseline demo-
graphics and characteristics were similar between anti-TNF-naive 
and anti-TNF-experienced patients in the ADA Randomized Set 
( Supplementary Table S1 ).
 Long-term efﬁ cacy outcomes
 Remission and mucosal healing rates were achieved early (data 
shown from week 8) and maintained through 4 years of treatment 
( Figure 2a–d ). At 1 year of maintenance therapy, 32.2% (193/600 
(NRI)) of patients randomized to adalimumab at lead-in study base-
line were in remission per PMS and 42.3% (254/600 (NRI)) of adal-
imumab-randomized patients had mucosal healing ( Figure 2a,b ). 
Rates at year 4 were 24.7% (148/600 (NRI)) and 27.7% (166/600 
(NRI)) for remission per PMS and mucosal healing, respectively. 
When patients from this analysis set who escalated to weekly dos-
ing were imputed as nonresponders (modifi ed NRI), the rate of 
remission per PMS was 27.3% at week 52 and 18.2% at week 
208 ( Figure 2a ). Of the 242 patients who entered ULTRA 3 in 
remission per full Mayo score, 78.5% (LOCF) and 63.6% (NRI) 
remained in remission per PMS 3 years later ( Figure 2c ). Of the 
409 patients who entered ULTRA 3 with mucosal healing, 81.7% 
(LOCF) and 59.9% (NRI) maintained mucosal healing through 
week 144 of ULTRA 3 ( Figure 2d ). Over time, remission and 
mucosal healing rates were generally greater in anti-TNF-naive 
compared with anti-TNF-experienced patients ( Supplementary 
Figure S1a,b ). During the fi rst 3 years of ULTRA 3, a total of 
120/588 (20.4%) patients in the ADA Extension Set escalated to 
weekly dosing. Mean PMS improved in this subgroup of patients 
from 6.0 (last PMS before moving to weekly dosing) to 3.0 (last 
weekly value).
 Predictors of loss of remission
 None of the variables analyzed at baseline of lead-in study or at 
the time of enrollment into ULTRA 3 was a signifi cant predictor 
of loss of remission ( Supplementary Table S2 ). In contrast, the 
time-dependent covariates CRP and albumin were signifi cantly 
associated with loss of remission. Patients with increasing CRP 
concentrations and decreasing serum albumin concentrations 
during ULTRA 3 were signifi cantly more likely to lose remission. 
Th e median time to loss of remission was not estimable for patients 
in the ADA Extension Set who entered ULTRA 3 in remission per 
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 Figure 1 .  Patient enrollment in the ULTRA studies. ( a ) Patient ﬂ ow into ULTRA 3. ADA, adalimumab; EOW, every other week; EW, weekly; OL, open label; 
ULTRA,  U lcerative Colitis  L ong- T erm  R emission and Maintenance with  A dalimumab. One patient in ULTRA 2 was randomized to adalimumab but did not 
receive the study drug. ( b ) The number of patients by study visit in the ADA Randomized Set and the ADA Extension Set. DB, double blind; PBO, placebo.
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 WPAI scores over time in adalimumab-randomized patients 
from ULTRA 2 are shown in  Supplementary Figure S3 . Mean 
percent scores for each WPAI component (work time missed, 
impairment while working, overall work impairment, and activ-
ity impairment) decreased from ULTRA 2 baseline through week 
208, indicating an improvement in work productivity and degree 
of activity impairment.
 Hospitalization and colectomy
 Incidence rates of hospitalizations and colectomy for patients dur-
ing ULTRA 3 were lower than those observed during the double-
blind treatment period of ULTRA 1 and 2 for patients receiving 
adalimumab dosing of 160/80/40 mg ( Table 1 ). Th is was observed 
for UC-related as well as for all-cause hospitalizations.
 Safety
 A total of 1,010 patients received at least one dose of adalimumab 
in ULTRA 1, 2, or 3, representing 2,338.0 patient-years of expo-
sure. An overview of treatment-emergent adverse events is shown 
in  Table 2 . Exposure-adjusted rates of adverse events in all adali-
mumab-treated patients during the entire treatment period were 
PMS, as more than half of the patients maintained remission dur-
ing the follow-up period ( Supplementary Figure S2 ).
 Maintenance of corticosteroid-free remission
 Th e corticosteroid-free remission rates for patients in the ADA 
Randomized Set who received corticosteroids at lead-in study 
baseline increased from week 52 (27.4%, 65/237) to week 196 
(39.7%, 48/121, observed analysis) of adalimumab treatment. 
Th e proportion of patients who discontinued corticosteroids 
increased over time from week 16 to week 208 of adalimumab 
treatment ( Figure 3 ).
 Health-related quality of life
 At 1 year of adalimumab maintenance therapy, 40.3% (242/600 
(NRI)) of patients in the ADA Randomized Set achieved remis-
sion per IBDQ score (IBDQ score ≥170). Remission rates per 
IBDQ score averaged between 26% and 36% throughout ULTRA 
3 ( Figure 4 ). Anti-TNF-naive patients had numerically higher 
rates of remission per IBDQ score relative to anti-TNF-experi-
enced patients throughout the entire duration of follow-up ( Sup-
plementary Figure S1c ).
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and gray bars indicate NRI analysis. ( d ) Maintenance of mucosal healing in patients who entered ULTRA 3 with mucosal healing from the ADA Extension 
Set ( N =409). Black bars indicate LOCF and gray bars indicate NRI analysis. ADA, adalimumab; LOCF, last observation carried forward; mNRI, modiﬁ ed 
nonresponder imputation; NRI, nonresponder imputation; ULTRA,  U lcerative Colitis  L ong- T erm  R emission and Maintenance with  A dalimumab.
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similar to or lower than those observed during the double-blind 
treatment period for patients receiving placebo or 160/80/40 mg 
adalimumab. Th e most frequently reported serious adverse event 
was worsening or fl are of UC. Two serious events of cytomegalo-
virus colitis were reported. Aft er the double-blind study period, 
one serious infection of tuberculosis and two treatment-emer-
gent fatal adverse events were reported. A fatal cardiorespiratory 
arrest occurred in a 35-year-old male who had previous expo-
sure to mercaptopurine and corticosteroids and for 3 days before 
his death suff ered from nonserious fl u syndrome, cephalgia, 
and myalgia. Right ventricular failure occurred in a 47-year-old 
female with a history of asthma, diabetes mellitus, hyperten-
sion, steatosis, and smoking. Th ree events of B-cell lymphoma 
occurred during ULTRA 3. All three patients had a history of 
smoking and either previous or concomitant azathioprine use. Of 
the patients randomized to adalimumab who were receiving con-
comitant corticosteroids and/or IMMs at lead-in study baseline, 
serious infection rates were similar to those observed for patients 
receiving adalimumab monotherapy (3.7 events/100 patient-years 
(E/100PY) adalimumab monotherapy, 3.0 E/100PY adalimumab 
with corticosteroids and without IMM, 3.6 E/100PY adalimumab 
with IMM and without corticosteroids, and 2.8 E/100PY adali-
mumab with corticosteroids and IMM).
 DISCUSSION
 Adalimumab is approved worldwide for the treatment of adult 
patients with moderately to severely active UC. Previously 
reported data demonstrating effi  cacy and safety in this patient 
population are limited to clinical trial data of up to 1 year  ( 6–9 ). 
Th is report presents a conservative estimate of the long-term effi  -
cacy and safety of adalimumab therapy with up to 4 years of fol-
low-up in patients with moderately to severely active disease. At 
year 4 of treatment, remission and mucosal healing were achieved 
by 24.7% and 27.7% (NRI), respectively, of patients initially ran-
domized to adalimumab at lead-in study baseline. Approximately 
60% of patients who entered ULTRA 3 and had achieved remis-
sion and mucosal healing at year 1 maintained these end points 
at year 4, when assessed using a conservative NRI methodology 
for missing data. No new safety concerns were observed, and the 
incidence of adverse events declined or remained stable over time.
 Th e safety profi le of up to 4 years of adalimumab therapy was 
consistent with adverse event rates reported from Crohn’s disease 
clinical trials and with the overall safety profi le of adalimumab 
across multiple indications  ( 11,14 ). Th e overall exposure-adjusted 
rate of adverse events observed during the 4-year follow-up period 
was lower than that observed during the double-blind period, and 
rates of infection and malignancy were stable over time. Of the 
three patients with B-cell lymphomas reported during ULTRA 3, 
all had previous or concomitant azathioprine use, a known risk 
factor for lymphoma in patients with IBD  ( 15,16 ). 
 Current treatment guidelines for patients with UC identify both 
control of symptoms and avoidance of colectomy and corticos-
teroid therapy as important treatment goals. Our results demon-
strated the favorable effi  cacy of long-term adalimumab treatment 
for patients with UC. Patients responded well to long-term ther-
apy, with stable remission and mucosal healing rates observed over 
4 years. Although the ADA Extension Set is a “selected” popula-
tion in that patients who completed the lead-in studies chose to 
continue therapy past 1 year, we show that prolonged adalimumab 
treatment is associated with maintenance of remission and mucosal 
healing in patients for an additional 3 years of follow-up. Further-
more, ongoing adalimumab treatment in these patients was associ-
ated with low rates of hospitalization and colectomy over time in 
patients with moderately to severely active UC. As an increase in 
colectomy and hospitalization incidence rates was not observed at 
later time points, our data support the idea that long-term adali-
mumab therapy is benefi cial for patients in avoiding these events 
and is not associated with a cumulative safety risk over time. Th e 
favorable eff ect of long-term adalimumab therapy is further dem-
onstrated by the observation that with ongoing therapy for 4 years, 
∼ 60% of patients receiving corticosteroids at the fi rst adalimumab 
dose discontinued corticosteroids and 40% were in corticosteroid-
free remission.
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≥170) over time in the ADA Randomized Set ( N =600). NRI analysis. ADA, 
adalimumab; IBDQ, Inﬂ ammatory Bowel Disease Questionnaire; NRI, 
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line had IBDQ-defi ned remission aft er 1 year of maintenance ther-
apy. IBDQ remission rates were sustained with ongoing therapy 
through the following 3 years. Work time missed remained low 
over time (between 4% and 7%) aft er 1 year of adalimumab treat-
ment. Taken together, these results have important implications in 
assessing the cost eff ectiveness of adalimumab therapy that will be 
evaluated in a separate analysis.
 Th e societal costs of ulcerative colitis, which include loss of 
employment, decreased work productivity, and loss of social 
function, are considerable. However, very few studies have demon-
strated the potential benefi t of anti-TNF therapy on such indirect 
costs. We observed important increases in work productivity that 
paralleled improved health-related quality of life. Approximately 
40% of patients randomized to adalimumab at lead-in study base-
 Table 1 .  Hospitalization and colectomy incidence rates for adalimumab-treated patients during double-blind and ULTRA 3 studies 
 Outcome  Weeks 0–52, a ADA 160/80/40 mg,  N =480,  n /PY at risk (IR)  ULTRA 3,  N=592,  n /PY at risk (IR) 
 A. Exposure-adjusted patient-based analysis of hospitalizations and colectomy ( n /PY (IR)) 
 All-cause hospitalization  69/387.5 (0.18)  135/1,455.0 (0.09) 
 UC-related hospitalization  47/398.1 (0.12)  59/1,658.6 (0.04) 
 Colectomy  15/408.1 (0.04)  16/1,709.3 (0.01) 
 B. Exposure-adjusted event-based analysis of hospitalizations ( n /PY (IR)) 
 All-cause hospitalization  85/410.2 (0.21)  204/1,711.5 (0.12) 
 UC-related hospitalization  56/410.2 (0.14)  86/1,711.5 (0.05) 
 ADA, adalimumab; IR, incidence rate; PY, patient-years; UC, ulcerative colitis; ULTRA 3,  U lcerative Colitis  L ong- T erm  R emission and Maintenance with  A dalimumab 3. 
 In (A),  n is the number of patients with event, and in (B)  n is the number of events. 
 a Week 52 data reported in Feagan  et al.  ( 10 ) . 
 Table 2 .  Treatment-emergent adverse event rates 
  DB exposure up to week 52  Exposure as of 15 April 2013 
  PBO,  N =483, PY=152.9, 
E (E/100 PY) 
 ADA (160/80/40 mg), a  N =480, 
PY=179.0, E (E/100 PY) 
 All ADA, N =1,010, PY=2338.0,  
E (E/100 PY) 
 Any AE  1,318 (862.2)  1,412 (789.0)  8,057 (344.6) 
 Serious AE  69 (45.1)  55 (30.7)  414 (17.7) 
 AE leading to discontinuation  63 (41.2)  39 (21.8)  249 (10.7) 
 Serious infection  10 (6.5)  4 (2.2)  79 (3.4) 
 Opportunistic infection (excluding TB)  1 (0.7)  2 (1.1)  6 (0.3) 
 Active tuberculosis  0  0  1 (<0.1) 
 Injection site reaction  25 (16.4)  84 (46.9)  246 (10.5) 
 Any malignancy incl. lymphoma  2 (1.3)  2 (1.1)  23 (1.0) b 
 Lymphoma  0  0  3 (0.1) 
 Congestive heart failure  0  1 (0.6)  4 (0.2) 
 Demyelinating disease  0  0  3 (0.1) 
 Hepatic event  0  0  12 (0.5) 
 UC worsening/ﬂ are  106 (69.4)  82 (45.8)  588 (25.2) 
 Death c  0  0  2 (0.1) 
 ADA, adalimumab; AE, adverse event; DB, double-blind; E/100PY, events/100 patient-years; incl., including; PBO, placebo; PY, patient-years; TB, tuberculosis; UC, 
ulcerative colitis. 
 a ADA 80/40/40 mg treatment group not shown. 
 b One malignant event was reported twice in the same patient. 
 c Only treatment-emergent deaths are shown. 
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 Maintaining remission for patients with chronic disease is an 
important goal for physicians, and identifying factors that may 
predict loss of remission is of great interest. None of the base-
line patient characteristics analyzed in this study was shown to 
be predictive of loss of remission. Instead, increasing CRP levels 
and decreasing albumin concentrations during treatment were 
identifi ed as signifi cant factors associated with a subsequent loss 
of remission. Th is fi nding is not unexpected as both CRP and 
albumin concentrations indicate the presence of infl ammation and 
may be early indicators of increasing disease activity, that subse-
quently results in a recurrence of symptoms.
 Th e use of a second anti-TNF agent in patients who have lost 
response to or become intolerant to treatment with a previous 
anti-TNF agent has generally been associated with lower effi  cacy, 
based on evidence from patients with Crohn’s disease  ( 17 ). Th is 
observation may relate to alterations in the underlying mecha-
nism of infl ammation of the disease, alterations in pharmacoki-
netics of the biologic agents being administered, or the presence of 
functional symptoms or symptoms related to alterations in bowel 
anatomy and physiology that are not amenable to anti-infl amma-
tory treatment. Th e adalimumab ULTRA 2 study allowed patients 
who had failed previous treatment with another anti-TNF agent 
to be enrolled. Data from this analysis indicated that patients with 
previous anti-TNF exposure tended to have lower rates of effi  cacy, 
although patients exhibiting a clinical response by week 8 have 
meaningful rates of longer-term effi  cacy, similar to anti-TNF-
naive patients  ( 7,9 ). During ULTRA 3, patients with previous 
anti-TNF exposure tended to have lower rates of remission (per 
PMS and per IBDQ score) and mucosal healing than patients who 
were anti-TNF naive, although some of these diff erences dimin-
ished at later time points. Th ese data suggest that patients with a 
history of failure to previous anti-TNF treatment can be consid-
ered candidates for treatment with a subsequent anti-TNF agent, 
although it is possible that it may take longer for these patients 
to achieve a full response than patients who are anti-TNF naive.
 Although the results presented here indicate that long-term 
adalimumab therapy is benefi cial for inducing and maintain-
ing remission in patients with UC, our study has several limita-
tions. First, in the overall study population, the timing of the fi rst 
adalimumab dose was not the same for each patient because of the 
protocol design. To overcome this, for the longitudinal effi  cacy 
analyses (from lead-in study baseline to week 208), we limited 
our assessments to a subset of all patients enrolled in ULTRA 1, 
2, and 3 (those randomized to adalimumab at lead-in study base-
line, 600/1,094) in order to report effi  cacy for the same treatment 
duration for all patients. As endoscopy-based outcomes, includ-
ing mucosal healing and remission per full Mayo score, could not 
be measured up to week 208 from fi rst adalimumab dose because 
most patients were not scheduled for endoscopy at this time, data 
could only be reported up to week 196 of treatment. Second, any 
long-term clinical study is hampered by loss of patient data over 
time due to premature discontinuation from the study for any 
reason (including, but not limited to, lack of effi  cacy or adverse 
events). In our analysis, we chose a very conservative estimate of 4 
years of adalimumab treatment, imputing noneffi  cacy for patients 
who discontinued study participation for any reason. Next, this 
analysis assessed symptom-based effi  cacy based on the worse rec-
tal bleeding and stool frequency Mayo subscores of 3 days before 
the study visit. Th is “worst rank” method may negatively infl uence 
these subscores (and the Physician’s Global Assessment subscore, 
as investigators were also instructed to consider the patient’s rectal 
bleeding subscore and stool frequency subscore when assigning 
the Physician’s Global Assessment subscore) and may underesti-
mate the benefi ts realized in clinical practice. Last, the data assess-
ments from ULTRA 3 refl ect clinical trial patients who completed 
the 1-year lead-in studies and may not fully refl ect real-world 
patients with moderate-to-severe UC. In addition, the rates of the 
clinical outcomes observed during ULTRA 3 may be infl uenced 
by the open-label design of the study. On the other hand, our 
study includes many positive features, including prespecifi ed and 
consistent follow-up conducted under the rigor of a GCP clinical 
study, and the variety of end points assessed allows characteriza-
tion of the impact of treatment on diff erent facets of the patient 
experience.
 In conclusion, this comprehensive report, which is based on data 
from multiple studies, demonstrates that prolonged adalimumab 
treatment for up to 4 years is well tolerated and is benefi cial for 
patients with moderately to severely active UC in maintaining 
remission and mucosal healing. Th e improvement in quality of life, 
work productivity, and low hospitalization and colectomy rates 
support the benefi t of long-term adalimumab therapy in a patient 
population who failed conventional therapy and/or previous anti-
TNF therapy.
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 Study Highlights
 WHAT IS CURRENT KNOWLEDGE 
 ✓  Adalimumab was more effective than placebo in inducing 
and maintaining remission in ulcerative colitis clinical trials. 
 ✓  The long-term safety and efﬁ cacy of adalimumab, beyond 
1 year, for ulcerative colitis has not been reported. 
 WHAT IS NEW HERE 
 ✓  Remission and mucosal healing rates were maintained with 
up to 4 years of adalimumab therapy. 
 ✓  Low colectomy and hospitalization rates and improvement 
in quality of life were observed with long-term adalimumab 
treatment. 
 ✓  No new safety risks were observed with prolonged adali-
mumab treatment. 
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